secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093930
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology reports Q2 net loss $39.4M; ASPEN-06 gastric cancer data shows ORR 40.3% vs 26.6%
--------------------------------------------------------------------------------

- GAAP net loss $39.4M ($0.76/sh) vs $34.2M ($0.84/sh) in Q2 2023; non-GAAP net loss $32.1M.
- Cash, equivalents and investments $186.2M; sufficient to fund operations into Q1 2026.
- R&D expenses $34.7M (up $5.2M YoY); G&A expenses $6.9M (down $0.4M YoY).
- ASPEN-06 Phase 2: Evo-TRP achieved 40.3% ORR vs 26.6% control; mDOR 15.7 vs 7.6 months in ITT.
- Phase 3 registrational trial in gastric/GEJ cancer expected to initiate mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017024093930/0000950170-24-093930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017024093930/alxo-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer